Andrew Moin
CIK: 0001996040
Associated companies
Transaction History
| SABS | ▲ Buy | Option Exercise | 1,740,000 | $3.0M | 9/29/2025 | View on chart |
| SABS | ▲ Buy | Option Exercise | 4,584,571 | — | 11/24/2023 | View on chart |
| SABS | ▲ Buy | Option Exercise | 1,740,000 | $3.0M | 9/29/2025 | View on chart |
| SABS | ▲ Buy | Option Exercise | 4,584,571 | — | 11/24/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
SAB Biotherapeutics to Present SAB-142 Data at European Diabetes Meeting
SAB Biotherapeutics will share results for its SAB‑142 program at the 62nd Annual Meeting of the European Association for the Study of Diabetes. The presentation offers a chance to update investors on the clinical progress of this diabetes therapy. The company’s stock is currently trading near its 15‑touch support level of $3.70 and shows a volume spike, indicating growing interest.
SAB Biotherapeutics to Present SAB-142 Data at European Diabetes Meeting. SAB Biotherapeutics will share results for its SAB‑142 program at the 62nd Annual Meeting of the European Association for the Study of Diabetes. The presentation offers a chance to update investors on the clinical progress of this diabetes therapy. The company’s stock is currently trading near its 15‑touch support level of $3.70 and shows a volume spike, indicating growing interest.